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Perioperative management of patients treated with
the non-vitamin K antagonist oral anticoagulants is
an ongoing challenge. Due to the lack of good clinical
studies involving adequate monitoring and reversal
therapies, management requires knowledge and
understanding of pharmacokinetics, renal function,
drug interactions, and evaluation of the surgical
bleeding risk. Consideration of the benefit of reversal
of anticoagulation is important and, for some low
risk bleeding procedures, it may be in the patient’s
interest to continue anticoagulation. In case of major
intra-operative bleeding in patients likely to have
therapeutic or supra-therapeutic levels of anticoagulation,
specific reversal agents/antidotes would be of value but
are currently lacking. As a consequence, a multimodal
approach should be taken which includes the
administration of 25 to 50 U/kg 4-factor prothrombin
complex concentrates or 30 to 50 U/kg activated
prothrombin complex concentrate (FEIBA®) in some
life-threatening situations. Finally, further studies are
needed to clarify the ideal therapeutic intervention.registry (The Dresden NOAC registry (NCT01588119),
Dresden, Germany), including patients treated withNon-vitamin K antagonist oral anticoagulants:
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Direct thrombin inhibitors, dabigatran etexilate (Pradaxa®,
Boehringer-Ingelheim Pharma GmbH, Ingelheim am Rhein,
Germany), and direct factor Xa inhibitors, rivaroxaban
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unless otherwise stated.oral anticoagulants (NOACs) increasingly used in the
treatment of venous thromboembolism, prevention of
cerebrovascular embolism in patients with atrial fibrillation,
and thromboprophylaxis in patients undergoing orthopedic
surgery [1]. Although the advantages of these new agents
include rapid onset (2 to 4 hours) of action, in addition to a
predictable anticoagulant effect without monitoring
requirements, different clinical conditions can impair their
pharmacokinetics and pharmacodynamics [2]. Despite
published management perspectives, strategies are not yet
clearly defined for perioperative management in patients
treated with NOACs.
However, a consistent finding is that NOACs may have
a lower bleeding risk. A recent report that included
27,419 patients treated for 6 to 36 months with dabigatran
or warfarin reported that 1,034 patients had 1,121 major
bleeding episodes during treatment or within 3 days of
temporary or permanent discontinuation of anticoagulation
[3]. The 30-day mortality after the first major bleed was
9.1% in the dabigatran group compared with 13.0% in the
warfarin group, and dabigatran-treated patients required a
shorter ICU stay compared with that in warfarin-treated
patients. Using data from a prospective, non-interventional
oral anticoagulants in the region of Dresden in Germany,
Beyer-Westendorf and colleagues [4] analyzed rates,
management, and outcome of rivaroxaban-related bleeding.
From 1,776 patients treated with rivaroxaban, 762 patients
(42.9%) experienced 1,082 bleeding episodes within 3 days
of discontinuation. Most episodes were classified as minor
(58.9%), but 35.0% experienced clinically relevant bleeding,
and 6.1% had major bleeding. The rates of major bleeding
per 100 patient-years were 3.4 (95% confidence interval
(CI) 2.6 to 4.4) for all patients, 3.1 (95% CI 2.2 to 4.3) for
patients anticoagulated in the context of atrial fibrillation,
and 4.1 (95% CI 2.5 to 6.4) for venous thromboembolism. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ventional treatment was needed in 37.8% and prothrombin
complex concentrates (PCCs) were administered in
9.1%. These results indicate that, in real life, rates of
rivaroxaban-related major bleeding may be lower than
with vitamin K antagonists (15 to 20%), and the outcome
may, at least, not be worse.
In approximately 25% of patients receiving NOACs,
treatment was interrupted at least once for surgery or
another invasive procedure [5,6]. In addition, managing
anticoagulation in the perioperative period is problem-
atic because all anticoagulants can cause bleeding [7].
Despite their apparent safety compared with warfarin,
perioperative management of patients treated with NOACs
is now a routine challenge. In a recent international survey,
we observed that physicians had limited knowledge about
the perioperative management of patients treated with
NOACs, and the management of emergency procedures
[8]. The goal of this article is to briefly review current
evidence, and propose an algorithm based on published
information for the perioperative management of patients
treated with NOACs.
Preoperative management of patients treated
with non-vitamin K antagonist oral anticoagulants
Preoperative management of patients treated with NOACs
will be influenced by different factors that include: (i) the
pharmacokinetic characteristics of the drug and the
possible interaction with other treatments; (ii) patient
comorbidities, especially renal function; and (iii) factors
related to surgery considering both the timing (elective or
urgent) and the bleeding risk of the procedure.
Dabigatran etexilate is a prodrug converted to an
active component, dabigatran, after an esterase-mediated
hydrolysis. This drug has a very low bio-availability (3 to
7%), and has a major renal mechanism for elimin-
ation (approximately 80%). Direct factor Xa inhibitors
(rivaroxaban, apixaban) are primarily metabolized by
the liver (65 to 70%), although renal excretion is also
present. Clinicians should consider that the half-life
of the three drugs is close to 12 hours in most patients [9].
Dabigatran elimination is most influenced by renal function,
and preoperative interruption should be based on creatinine
clearance (CrCl) calculated according to the Cockcroft and
Gault formula [10]. Patients with moderate renal impair-
ment (CrCl of 30 to 50 ml/minute) demonstrated >2-fold
higher plasma levels compared with subjects with normal
renal function (CrCl >80 ml/minute) [11]. Although the
bleeding risk reported in the RE-LY trial was lower with
dabigatran in the presence of normal renal function,
the rates of major bleeding were higher as renal function
deteriorated [12]. Renal function is less an issue with
rivaroxaban and apixaban until severe renal insufficiency
occurs [13]. Drug interactions are less important withNOACs than vitamin K antagonists, but the following
interactions are relevant: aspirin, non-steroidal anti-
inflammatory drugs, P-glycoprotein inhibitors (for example,
amiodarone), CYP3A4 inhibitors (for example, phenotiazin),
or inducers (for example, alcohol, carbamazepine) are
at increased risk of abnormal metabolism. Notably, more
than 40% of the targeted population, aged >75 years old,
receive at least one of these drugs [14].
Different groups have published recommendations
for perioperative management [15-19]. As recently
recommended by the European Society of Cardiology
[9], surgical procedures should be classified in three
different categories: (i) interventions not requiring
discontinuation of anticoagulation (for example, dental,
ophthalmology, and superficial surgeries); (ii) intervention
with low bleeding risk (for example, prostate or bladder
biopsy, angiography, pacemaker implementation); or (iii)
intervention with high bleeding risk (spinal or epidural
anesthesia, lumbar diagnostic puncture, cardiothoracic
surgery, abdominal surgery, major orthopedic surgery,
liver biopsy, transurethral prostate resection, and kidney
biopsy). Based on these guidelines [9,16,18], the three
NOACs currently available should be stopped 24 hours
before surgery with a low bleeding risk, and at least
48 hours and up to 96 hours before surgery with a high
bleeding risk. In case of severe renal impairment
(CrCl <30 ml/minute), interruption of direct factor
Xa inhibitors should be delayed to 48 hours. For
dabigatran, delays should be progressively prolonged
based on CrCl (Figure 1) and potential laboratory testing
should be considered to determine residual effects of the
agents. It is important to mention that the use of
dabigatran in patients with severe renal impairment
(CrCl <30 ml/minute) is not recommended. Another way
to manage these agents is to define a more conservative
approach and to recommend the same interruption period
for all the NOACs. With this approach, interruption
should be 4 days in all patients and, in some cases
(elderly, severe renal insufficiency), the interruption
should approach 5 days. Additional studies are needed
to optimize perioperative management.
In another analysis from the Dresden registry, Beyer-
Westendorf and colleagues [6] assessed the management
and the safety of perioperative NOAC use in 2,179 patients,
of which 595 underwent 863 surgical procedures. Major
cardiovascular events and major bleeding complica-
tions were low (1.0 and 1.2% after major procedures).
Preoperative heparin bridging did not reduce the inci-
dence of cardiovascular events, but was associated with an
increased risk of major bleeding compared with the
‘no-bridging’ approach, especially in patients who under-
went major procedures. This study reported that a short
preoperative interruption was safe in patients who under-
went either minor or major procedures. In case of major
Figure 1 Proposed algorithm for peri-operative management of non-vitamin K antagonist oral anticoagulants. CrCl, creatinine clearance; LMWH,
low molecular weight heparin; NA, not applicable; NOAC, non-vitamin K antagonist oral anticoagulant; PCC, prothrombin complex concentrate;
TE, thromboembolism.
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a decreased incidence of cardiovascular event, while it
significantly increased the bleeding risk. However, the
benefit should always be balanced with the thromboembolic
risk in high-risk patients. The role of additional coagulation
testing, either specific (diluted thrombin time or specific
anti-Xa activity) or non-specific (for example, activated
partial thromboplastin time, and prothrombin time (PT)),
in the preoperative management of NOACs for elective
procedures needs to be determined.
Managing patients that require an emergency surgical
procedure is an ongoing challenge. The timing between
the last intake and the incident should be checked.Specific tests for NOACs effects are important to consider,
and normal standard coagulation tests, PT or activated
partial thromboplastin time, may not exclude the presence
of clinically relevant concentrations of NOACs [20]. The
effects of dabigatran can be assessed using specific
diluted thrombin times (Haemoclot®) and direct factor
Xa inhibitors require specific antifactor-Xa assays which
are now available in the market. For both tests, results are
expressed as ng/ml [21,22]. In recent published pro-
posals, Pernod and colleagues and the GIHP group
(Groupe d’Intérêt en Hémostase Périopératoire) [23]
suggested that the measurement of the NOACs plasma
concentration should be considered as the best way to
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the bleeding risk. If the plasma concentration is below
30 ng/ml, the surgery could be safely performed.
Between 30 and 200 ng/ml, surgery should be delayed
for at least 12 hours and testing repeated each
12 hours until the concentration reaches a safe level
(<30 ng/ml). At concentration between 200 and
400 ng/ml, surgery should be delayed a minimal period of
24 hours. In patients with renal dysfunction treated with
dabigatran, the relationship between concentration
thresholds and time delays based on pharmacokinetics
may be inaccurate. Dabigatran levels >400 ng/ml pose
a major risk of uncontrollable hemorrhage, and
hemodialysis should be considered. In the context of
emergency procedures, the benefit associated with a sur-
gery performed within a short delay should be balanced
with the risk of major hemorrhage.
Postoperative anticoagulation
Postoperative management of NOACs should be considered
as restarting any anticoagulation agent in this setting. With
appropriate hemostasis, NOACs potentially can be resumed
6 to 8 hours after minor procedures [9]. However, restarting
full dose anticoagulation shortly after a procedure may
increase the risk of postoperative bleeding. If this risk
outweighs the risk of thromboembolic complication, full
dose anticoagulation might be resumed 48 or 72 hours after
the procedure [24]. In case of immobilization and increased
risk of thromboembolic complication, thromboprophylaxis
using low molecular weight heparins or unfractionated
heparin should be started within 6 to 8 postoperative hours,
whereas therapeutic anticoagulation with NOACs should be
delayed for 48 to 72 hours after the procedure (Figure 1).
Following major orthopedic surgery it may be appropriate
to use prophylactic doses of NOACs until the patient can
resume full dose anticoagulation.
Intraoperative or postoperative bleeding
management
There is limited information on the management of
bleeding events in patients treated with NOACs. In a
recent review of animal and human studies, Lee and
colleagues [25] reported that although more than 15
trials assessed the effect of different treatment strat-
egies to reverse the effect of NOACs, only two were
performed in human volunteers, concluding that most
of our experience came from animal bleeding models.
In 2011, Eerenberg and colleagues [26] reported that
administration of PCCs in healthy volunteers who received
dabigatran 150 mg twice in one day improved laboratory
parameters (PT and thrombin generation) but did not
restore them to baseline. In another study performed
in healthy volunteers, the authors reported that for both
dabigatran and rivaroxaban, lower doses of activated PCCs(FEIBA® Baxter Healthcare, Westlake Village, CA,USA)
appeared to be able to reverse the anticoagulant activity
ex vivo in blood samples [27]. Although attempts were
made to restore anticoagulant-induced bleeding using
non-specific reversal agents, the current literature is
suboptimal and clinical evaluations are needed regarding
hemorrhagic situations. Only a few cases reported the
efficacy of PCCs for urgent reversal of dabigatran in
emergency situations [28].
Actually, preclinical data suggest that both prothrombin
complex concentrates (three- or four-factor PCCs, 25 to
100 U/kg) and activated PCCs (FEIBA®, 20–80 U/kg), and
recombinant activated factor VII (rFVIIa 90 μg/kg) can
potentially correct the anticoagulation in case of massive
bleeding after application of standard therapies (for
example, fluid replacement, tranexamic acid) [29-33].
In a recent study performed in healthy volunteers,
Levi and colleagues [34] confirmed that after receiving
4 days of rivaroxaban 20 mg twice in one day to obtain
supra-therapeutic steady-state concentrations, both three-
and four-factor PCCs partially reversed the anticoagulant
effects of rivaroxaban in healthy adults. Administration of
either the four-factor PCCs or the three-factor PCCs was
safe and well tolerated, with no signs of thromboembolic
events. Although discrepancy was reported between the
effects of the two products on coagulation assays, the
different effect observed for PT and thrombin generation
are currently unclear.
Based on current literature, mainly from animal experi-
mentations and preclinical studies, the off-label therapeutic
use of both non-activated PCC (20 to 50 U/kg) and
activated PCC (FEIBA®, 30 to 50 U/kg) may be considered
for bleeding management in patients likely to have thera-
peutic or supra-therapeutic levels of NOACs (Figure 1)
[35], although FEIBA®, and its high potential to overshoot
thrombin generation, might be more effective in case of
life-threatening bleeding; this benefit might be balanced
with an increased risk of thrombosis [36]. Considering
that no benefit was reported with the administration
of rFVIIa alone, while this component could also be
associated with a significant increase in the incidence
of fatal thromboembolic complication [37], there is
no evidence to support the use of rFVIIa.
Further specific antidotes are currently under devel-
opment and will probably solve the issue of bleeding
management [38,39]. Although hemodialysis could be
an option in case of dabigatran-induced hemorrhage,
little evidence exists and this solution should be limited
to overdose with an increased risk of life-threatening
hemorrhage [40]. In a recent study, Wang and colleagues
reported that activated charcoal decreased the mean half-
live of apixaban to 5 hours when charcoal was administered
within 6 hours after the ingestion of the drug [41]. In
the British Committee for Standards in Haematology
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was recommended in bleeding patients who have taken a
dose of dabigatran in the last 2 hours [19]. This short
delay limits its use in our clinical practice.Conclusion
Perioperative management of patients treated with NOACs
is an ongoing challenge. Specific recommendations have
been made regarding management, but again are based on
expert opinion (Figure 1). Due to the lack of good clinical
studies involving adequate monitoring and reversal
therapies, management requires knowledge and under-
standing of pharmacokinetics, renal function, drug inter-
actions, and evaluation of the surgical bleeding risk.
Consideration of the benefit of reversal of anticoagulation
is important and for some low risk bleeding proce-
dures it may be in the patient’s interest to continue
anticoagulation. In case of major intra-operative bleeding
where anticoagulation is thought to contribute substantially
to the bleeding, standard therapy should include a
multimodal approach including the administration of
25 to 50 U/kg four-factor PCCs or 30/50 U/kg activated
PCCs (FEIBA®). Specific reversal agents/antidotes would
be of value but are currently lacking. Finally, further
studies are needed to clarify the ideal therapeutic
intervention.
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